4919-33-9

Basic information

• Product Name: 4-ETHOXYPHENYLACETIC ACID
• Synonyms: ASISCHEM D13368;4-ETHOXYPHENYLACETIC ACID;VITAS-BB TBB000370;RARECHEM AL BO 0341;P-ETHOXYPHENYLACETIC ACID;P-ETHOXY-A-TOLUIC ACID;PARA ETHOXYL PHENYL ACETIC ACID;4-ethoxy-benzeneaceticaci
• CAS NO: 4919-33-9
• Molecular Formula: C₁₀H₁₂O₃
• Molecular Weight: 180.2
• EINECS: 225-545-3
• Product Categories: Aromatic Phenylacetic Acids and Derivatives
• Mol File: 4919-33-9.mol

Chemical Properties

• Melting Point: 87-90 °C(lit.)
• Boiling Point: 318.5±17.0℃ (760 Torr)
• Flash Point: 125.8±14.4℃
• Appearance: White to beige/Crystalline Powder
• Density: 1.144±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.000151mmHg at 25°C
• Refractive Index: 1.5430 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.46±0.10(Predicted)
• BRN: 1103143
• CAS DataBase Reference: 4-ETHOXYPHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ETHOXYPHENYLACETIC ACID(4919-33-9)
• EPA Substance Registry System: 4-ETHOXYPHENYLACETIC ACID(4919-33-9)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 37/39-26
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 4919-33-9(Hazardous Substances Data)

Usage

Chemical Properties

white to beige crystalline powder

InChI:InChI=1/C10H12O3/c1-2-13-9-5-3-8(4-6-9)7-10(11)12/h3-6H,2,7H2,1H3,(H,11,12)/p-1

Upstream product

• 64-67-5 diethyl sulfate 
• 14191-95-8 4-cyanomethylphenol 
• 156-38-7 4-hydroxyphenylacetate 
• 4947-83-5 4-[(4-ethoxy-phenyl)-thioacetyl]-morpholine 
• 6775-77-5 4-ethoxyphenylacetonitrile 
• 860368-91-8 4',7-diethoxy-5-hydroxyisoflavone 
• 1197-55-3 4-aminophenylacetic acid 
• 622-60-6 1-ethoxy-4-methylbenzene 
• 40784-88-1 ethyl 4-ethoxyphenylacetate 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 29056-03-9 4-ethoxyphenylacetic acid methyl ester 
• 75-03-6 ethyl iodide 

Downstream Products

• 40784-88-1 ethyl 4-ethoxyphenylacetate 
• 725732-38-7 3,4'-diethoxy-6-hydroxy-2,4-dimethoxy-deoxybenzoin 
• 50690-57-8 4'-ethoxy-deoxybenzoin 
• 10368-35-1 4-ethoxyphenylacetic acid chloride 
• 101451-64-3 ((Ξ)-4-ethoxy-benzylidene)-phthalide 
• 132353-99-2 (4-Ethoxy-phenyl)-thioacetic acid S-methyl ester 
• 110191-36-1 4-Benzyloxy-2-(4-ethoxy-benzyl)-7-methyl-1H-benzoimidazole 
• 33468-11-0 4-n-Butyl-4'-ethoxy-β-methyl-trans-stilben 
• 33468-12-1 4-n-Butyl-4'-ethoxy-α-methyl-trans-stilben 
• 36935-40-7 4'-Ethoxy-4-(3-methylbutyl)-α-chlor-trans-stilben 
• 33468-13-2 4-n-Butyl-4'-ethoxy-β-chlor-trans-stilben 
• 33468-14-3 4-n-Butyl-4'-ethoxy-α-chlor-trans-stilben 
• 33468-09-6 4-n-Butyl-4'-ethoxy-trans-stilben 
• 36931-17-6 4'-Ethoxy-4-n-pentyl-α-chlor-trans-stilben 

Relevant articles and documents

C1 substituted 3, 4 - ISO-quinoline alkaloids of the preparation and its medicinal use

The invention belongs to the field of medical technology. The invention relates to a structure of the formula (I) indicated by the C1 substituted 3, 4 - ISO alkaloid or its pharmaceutically acceptable salt preparation method and medical use thereof. The invention to BOC - L - phenylalanine as raw materials, with 3, 4 - dimethoxyphenethylamine to N - acylated condensation and then remove the BOC group gets the (S)- 2 - amino - N - (3, 4 - dimethyl practiced with ethyl) - 3 - benzyl amide intermediate 1, intermediate 1 or phenethylamine derivatives with the prepared containing different substituent phenyllacetyl carries out amidation reaction, finally loop Bischler - Napieralski reaction. After activeness screening tests, the compounds of this invention possess pancrelipase inhibition, in the development into a lipase inhibitor and for preventing or treating hyperlipidemia, diabetes, obesity or metabolic syndrome and other diseases has a good application prospect.

9 - Substituted derivative of berberine at the preparation and its use in medicine (by machine translation)

The invention belongs to the field of medical technology. The invention relates to a structure of the formula (I) and formula (II) shown by the 9 bit - substituted berberine derivatives and their pharmaceutically acceptable salts thereof and its medical use. After activeness screening tests, the compounds of this invention possess pancrelipase inhibition, develop into the prospect of lipase inhibitors; in addition, the compounds of this invention fat-soluble than berberine increased, so that the development into the prevention or treatment of hyperlipidemia, diabetes, obesity or metabolic syndrome and other diseases in more application prospect. (by machine translation)

PROCESS FOR SYNTHESIZING PHENYLACETIC ACID BY CARBONYLATION OF TOLUENE

A production process for substituted phenylacetic acids or ester analogues thereof is disclosed. In this process toluene or toluene substituted with various substituents, an alcohol, an oxidant and carbon monoxide are used as raw materials to obtain compounds comprising structure of phenylacetic acid ester or analogues thereof by catalysis of the complex catalyst formed from transition metal and ligand, and such compounds are hydrolyzed to obtain various substituted phenylacetic acid based compounds. This type of compounds and their derivatives serve as important fine chemicals used widely in the industries of pharmaceuticals, pesticides, perfume and the like.

Design, synthesis and in vivo hypoglycemic activity of tetrazole-bearing N-glycosides as SGLT2 inhibitors

Novel tetrazole-bearing N-glycosides have been designed and synthesized as SGLT2 inhibitors via a conventional protocol starting from substituted phenylacetic acids and two monosaccharides, D-glucose and D-galactose, and their hypoglycemic activity has been tested in vivo by mice oral glucose tolerance test (OGTT). Two compounds are found to be more potent than the positive control Dapagliflozin. The structure-activity relationship has also been investigated.

Method of inhibiting sweetness

The sweetness of an ingestible product containing a sweetening sugar or sugar alcohol in large quantities can be reduced by incorporating therein a sweetness-reducing amount of at least one compound of the general formula: STR1 in which m represents 0 or 1, and when m represents 0, n represents 1, 2 or 3, and p represents 1, 2, 3 or 4, and when m represents 1, n represents 1 or 2 and p represents 0, 1, 2, 3 or 4; the substituents R, which may be the same or different, each represent a lower alkoxy group, e.g. with 1 to 5 carbon atoms, phenoxy group or a lower alkyl or trifluoromethyl group; and/or two substituents R together represent an aliphatic chain linked to the phenyl ring at two positions, either directly or via an oxa-group, e.g. an alkylenedioxy, alkenylenedioxy, alkylenoxy or alkenylenoxy group; and/or one substituent R represents a hydroxy group while at least one other substituent R represents an alkoxy group; and X+ represents a physiologically acceptable cation.